Tryptamine Therapeutics Ltd
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more
Tryptamine Therapeutics Ltd (TYP) - Total Liabilities
Latest total liabilities as of December 2023: AU$367.88K AUD
Based on the latest financial reports, Tryptamine Therapeutics Ltd (TYP) has total liabilities worth AU$367.88K AUD as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tryptamine Therapeutics Ltd - Total Liabilities Trend (2016–2023)
This chart illustrates how Tryptamine Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tryptamine Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Tryptamine Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Force MOS Technology Co., LTD.
TWO:4923
|
Taiwan | NT$426.47 Million |
|
Fitzroy Minerals Inc
OTCQB:FTZFF
|
USA | $768.34K |
|
Safe Fertility Group Public Company Limited
BK:SAFE
|
Thailand | ฿213.74 Million |
|
Lippo Malls Indonesia Retail Trust
PINK:LPMDF
|
USA | $894.47 Million |
|
Mico BioMed Co. Ltd.
KQ:214610
|
Korea | ₩7.88 Billion |
|
Wisr Ltd
AU:WZR
|
Australia | AU$976.80 Million |
|
Sýn hf
IC:SYN
|
Iceland | Ikr22.30 Billion |
Liability Composition Analysis (2016–2023)
This chart breaks down Tryptamine Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tryptamine Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tryptamine Therapeutics Ltd (2016–2023)
The table below shows the annual total liabilities of Tryptamine Therapeutics Ltd from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-06-30 | AU$1.75 Million | -63.50% |
| 2022-06-30 | AU$4.81 Million | +85.57% |
| 2021-06-30 | AU$2.59 Million | +69.81% |
| 2020-06-30 | AU$1.53 Million | +442.75% |
| 2019-06-30 | AU$281.00K | +299.15% |
| 2018-06-30 | AU$70.40K | +9150.99% |
| 2017-06-30 | AU$761.00 | +288.27% |
| 2016-06-30 | AU$196.00 | -- |